|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Can Yücel Karabay
Dr. Muzaffer Kahyaoğlu
Contributors
Dr. Ahmet Caner Canpolat
Dr. Aysu Oktay
Dr. Hadi Verdiyev
Dr. Kemal Göçer
Dr. Mehmet Altunova
Dr. Mehmet Murat Yiğitbaşı
Dr. Merve Kapçık
Dr. Muhammed Ali Söyler
Dr. Muhammet Ali Ekiz
Dr. Mustafa Yenerçağ
Dr. Mustafa Yılmaz
Dr. Özkan Karaca
Dr. Ramazan Furkan Demirkıran
Dr. Seda Kurat Güldoğmuş
Dr. Sefa Sarı
Dr. Selim Süleyman Sert
Dr. Serkan Bulguroğlu
Dr. Ülkü Nur Koç
Dr. Yücel Kanal
|
| |
|
|
|
Pooled analysis of two randomised controlled trials comparing balloon-expandable TAVI valvesTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - Pooled analysis of two randomised controlled trials comparing balloon-expandable TAVI valves (Dr. Muhammed Ali Söyler)Prepared by: Dr. Muhammed Ali Söyler
Name of Study: Pooled analysis of two randomised controlled trials comparing balloon-expandable TAVI valves
Published in: EuroPCR 2025
Link: https://course.pcronline.com/en/vod/hotline-tavi-2-outcomes-new-and-established-devices
Introduction:
Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive procedure used for severe symptomatic aortic stenosis,especially those who are at high risk for surgical valve replacement. There are different types of valve types such as balloon expandable (e.g. SAPIEN 3), self expanding (e.g. Evolut) and newer generation valves (e.g. Myval) In this study main purpose is a compare the performance of new Myval/Myval Octacor THVs with the already known well SAPIEN 3/ SAPIAN 3 ULTRA for short and long term performance differences.
Objective:
To directly compare the performance of Myval/Myval Octacor valves with the well known SAPIEN3/SAPIEN 3 Ultra.
Methods:
This multicentre, all-comers, randomized, non-inferiority trial was done at different hospitals. Suitable patients arranged for TAVI procedure. For the procedure, SAPIEN 3 /SAPIEN 3 ULTRA or Myval/Myval Octacor valves used. Patients were randomly assigned to treatment with SAPIEN 3 or SAPIEN 3 Ultra or Myval or Myval Octacor. The primary endpoint was a composite death, stroke, aortic regurgitation, and valve detoriation at a 1 year time. Also, compare new permenant pacemaker need, hemodynamic findings, and subgroup analysis of Myval and Myval Octacor with SAPIEN valves.
Results:
In this 2 different trial, COMPARE TAVI 1 and LANDMARK, 709 patients used SAPIEN3/SAPIEN 3 ULTRA and 898 patients used Myval/Myval Octacor. Average age for Sapien group was 81.3 and for Myval group 81.2. Totally 293 (41.3%) patient was female in Sapien group and 401(44.7%) was female in Myval group. Primary composite endpoit for SAPIEN 3 series was 90/709 (12.7%) and for Myval series 119/898 (13.3%). For SAPIEN 3 series 1 year death 44/709 and for Myval series 55/898 (p=0.96). For SAPIEN series stroke in year 31/709 and for Myval stroke in 1 year 47/898 (p=0.42). For secondary endpoints, new permenant pacemaker need in SAPIEN series 91/654 (13.9%) and for Myval series 159/828 (19.2%).
Conclusion:
In these trials show us one of new generation aortic valve Myval/Myval octacor are met the nonferiority margin, indicating that Myval / Myval octacor aortic valves are comperable to SAPIEN3/SAPIEN 3 Ultra.
Commentary:
These trials are important for us to compare evolution of transcatheter heart valve technologies. And similar results for Myval and SAPIEN aortic valves shows us that Myval is a reliable alterntive for SAPIEN aortic valves.
|
